caa a22 4500 605490988 CHVBK 20210128100507.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0747-6 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0747-6 The correlation between plasma aprepitant concentration and antiemetic effect in Japanese gastric or esophageal cancer patients [Elektronische Daten] [Kosuke Nishizawa, Hideaki Shimada, Masaaki Ito, Yoko Oshima, Satoshi Yajima, Yoshinori Kikuchi, Yasukiyo Sumino, Hironori Kaneko, Kenji Nishizawa, Masahiko Obayashi] Background: Chemotherapy-induced nausea and vomiting (CINV) are significant problems in cancer patients, but a correlation between plasma aprepitant concentration and antiemetic effect has not been reported. This study aimed to characterize the correlation between plasma aprepitant concentration and clinical antiemetic effect in a limited group of Japanese gastric or esophageal cancer patients. Methods: Thirty-three Japanese cancer patients receiving cisplatin-based chemotherapy for the first time following oral aprepitant (125mg on day 1 and 80mg on days 2 and 3) were enrolled. The plasma aprepitant concentrations 48h after the first administration were determined using liquid chromatography-mass spectrometry. Patients were allocated to the high-concentration group (plasma aprepitant concentration was >331.1ng/ml) or the low-concentration group (plasma aprepitant concentration was ≤331.1ng/ml) to investigate the relationship between plasma aprepitant concentration and antiemetic effects. Results: No significant differences were found between the two groups in terms of percentage of CINV prevention. Of 13 patients who experienced CINV [MASCC Antiemesis Tool (MAT) score >3], those in the high-concentration group showed a significant improvement in CINV following aprepitant administration (days 1-3). Conclusion: The present study suggests that the antiemetic effect of aprepitant is associated with plasma aprepitant concentration. A plasma aprepitant concentration of 331.1ng/ml may be a valid threshold for identifying its optimal antiemetic effects in Japanese gastric or esophageal cancer patients. Japan Society of Clinical Oncology, 2014 Chemotherapy nationallicence Nausea nationallicence Vomiting nationallicence Aprepitant nationallicence Nishizawa Kosuke Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Shimada Hideaki Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Ito Masaaki Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Oshima Yoko Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Yajima Satoshi Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Kikuchi Yoshinori Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan aut Sumino Yasukiyo Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan aut Kaneko Hironori Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Nishizawa Kenji Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut Obayashi Masahiko Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, Toho University, 2-2-1, Miyama, 274-8510, Funabashi, Chiba, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 538-542 1341-9625 20:3<538 2015 20 10147 https://doi.org/10.1007/s10147-014-0747-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0747-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nishizawa Kosuke Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Shimada Hideaki Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Ito Masaaki Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Oshima Yoko Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Yajima Satoshi Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Kikuchi Yoshinori Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan aut NATIONALLICENCE 700 1- Sumino Yasukiyo Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan aut NATIONALLICENCE 700 1- Kaneko Hironori Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Nishizawa Kenji Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan aut NATIONALLICENCE 700 1- Obayashi Masahiko Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, Toho University, 2-2-1, Miyama, 274-8510, Funabashi, Chiba, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 538-542 1341-9625 20:3<538 2015 20 10147